Related Experiment Videos
Polyarginines are potent furin inhibitors
A Cameron1, J Appel, R A Houghten
1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.
The Journal of Biological Chemistry
|August 26, 2000
Summary
Researchers identified potent, small molecule inhibitors for the enzyme furin, crucial in diseases like cancer and infections. Nona-L-arginine and related polyarginines show high potency and specificity, offering potential therapeutic leads.
Area of Science:
- Biochemistry
- Enzymology
- Drug Discovery
Background:
- Furin, a serine endoprotease, is vital in activating bacterial toxins, viral glycoproteins, and promoting tumor metastasis.
- Existing high molecular mass serpin inhibitors lack small, non-toxic, nanomolar alternatives.
- Need for novel, potent, and specific furin inhibitors for therapeutic applications.
Purpose of the Study:
- To identify small, non-toxic, nanomolar inhibitors of the enzyme furin.
- To explore the structure-activity relationships of peptide inhibitors.
- To evaluate the potential of polyarginine derivatives as therapeutic leads.
Main Methods:
- Utilized positional scanning of synthetic L- and D-hexapeptide combinatorial libraries.
- Synthesized and tested non-amidated and acetylated polyarginines.
- Determined inhibition constants (K(i)) against furin, PACE4, and prohormone convertase-1 (PC1).
Main Results:
- Nona-L-arginine identified as a potent furin inhibitor (K(i) = 40 nm).
- Hexa-L-arginine and Hexa-D-arginine demonstrated significant potency and specificity for furin.
- Polyarginines showed varying inhibition profiles against related convertases (PACE4, PC1) and no inhibition of PC2.
Conclusions:
- Non-acetylated, poly-D-arginine derivatives are promising lead compounds for developing therapeutic furin inhibitors.
- Furin's extended subsite recognition influences inhibitor potency and specificity.
- Polyarginines offer a novel scaffold for targeting furin-related pathologies.